Perceived functioning, well-being and psychiatric symptoms in patients with stable schizophrenia treated with long-acting risperidone for 1 year.
about
Second-generation long-acting injectable antipsychotics in schizophrenia: patient functioning and quality of lifeQuality of life is predictive of relapse in schizophrenia.Clinical outcomes of long-acting injectable risperidone in patients with schizophrenia: six-month follow-up from the Electronic Schizophrenia Treatment Adherence Registry in Latin America.Symptom domains of schizophrenia: the role of atypical antipsychotic agents.The relationship between patient satisfaction and treatment outcomes in schizophrenia.The case for long-acting antipsychotic agents in the post-CATIE era.Self-Evaluation of Negative Symptoms: A Novel Tool to Assess Negative Symptoms.Social functioning as an outcome measure in schizophrenia studies.Risperidone long-acting injection: a review of its long term safety and efficacy.Psychiatrists' perceptions of the clinical importance, assessment and management of patient functioning in schizophrenia in Europe, the Middle East and Africa.Use of long-acting risperidone in psychiatric disorders: focus on efficacy, safety and cost-effectiveness.Long-acting risperidone injection: efficacy, safety, and cost-effectiveness of the first long-acting atypical antipsychotic.Expected clinical benefits of paliperidone extended-release formulation when compared with risperidone immediate-release.Can small molecules provide truly effective enhancement of cognition? Current achievements and future directions.Real-world evaluation of the Resident Assessment Instrument-Mental Health assessment system.Reliability and validity of a brief self-rated scale of health condition with acute schizophrenia.Flourishing With Psychosis: A Prospective Examination on the Interactions Between Clinical, Functional, and Personal Recovery Processes on Well-being Among Individuals with Schizophrenia Spectrum Disorders.Dimensional symptom severity and global cognitive function predict subjective quality of life in patients with schizophrenia and healthy adults.Exploring the response shift effect on the quality of life of patients with schizophrenia: an application of the random forest method.Relationship between improvements of subjective well-being and depressive symptoms during acute treatment of schizophrenia with atypical antipsychotics.Effects of the two-way communication checklist (2-COM): a one-year cluster randomized study in a group of severely mentally ill persons.Patient preferences concerning the efficacy and side-effect profile of schizophrenia medications: a survey of patients living with schizophrenia
P2860
Q26752965-E1E1CF08-17C3-428F-ABBA-B57C032035C2Q34542824-0DD92DDE-AC00-4FC8-9B46-A17BBA160990Q34560335-53ACDC4F-3041-450C-A29B-83F6FC1BF789Q36626242-29096862-ADD8-4F93-9CAA-AE4772B8DF01Q36626251-94C95549-53A8-4FDA-B129-7631A4D85D88Q36758680-CA17F5E0-97D3-425C-8246-D78CF8354915Q36817178-63539143-79E0-4D62-9489-233EDEBDD703Q36973846-037C3D6F-6ED6-4D2F-A659-D81017C6E7A8Q37062563-66E3F7E1-1167-41B8-8E85-D50F12F1B799Q37187202-E1B933EF-8264-4BF0-AE7B-5861B8B5E7C6Q37356486-F1B531BF-7234-4C8E-81DA-38AE989C51CEQ37418931-D94F733C-05EA-458E-8D8C-39808DC519A7Q37422493-E64AC6CB-FBBA-48B9-BC11-2CCAA5CD7B35Q37867702-931C3D79-BD2F-45D0-A716-C34A94143EEAQ38059576-B300D322-0E05-4619-AD30-8384B675B0F0Q44002444-11FA9773-7401-4BCA-A08A-99855127AB4FQ47605577-0F39E397-1FBE-4CDC-9666-E5EF2CAA32C2Q47732483-E7B32A11-A6C2-4563-8D19-D0948B8DC191Q48059796-F24ED515-1336-4ABF-B627-E8A74CBA1957Q48900090-2B6910AB-424E-4D17-BFAD-D26D03F06A88Q50730864-C246C528-DBA2-4014-AF2D-4C4D278D9F4FQ58746697-BE9A4A89-42D2-47A6-A5DE-326EA3089CFA
P2860
Perceived functioning, well-being and psychiatric symptoms in patients with stable schizophrenia treated with long-acting risperidone for 1 year.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh-hant
name
Perceived functioning, well-be ...... acting risperidone for 1 year.
@en
Perceived functioning, well-be ...... acting risperidone for 1 year.
@nl
type
label
Perceived functioning, well-be ...... acting risperidone for 1 year.
@en
Perceived functioning, well-be ...... acting risperidone for 1 year.
@nl
prefLabel
Perceived functioning, well-be ...... acting risperidone for 1 year.
@en
Perceived functioning, well-be ...... acting risperidone for 1 year.
@nl
P2093
P356
P1476
Perceived functioning, well-be ...... acting risperidone for 1 year.
@en
P2093
Angelika Mehnert
Georg Kemmler
Jonathan Rabinowitz
Mariëlle Eerdekens
W Wolfgang Fleischhacker
P304
P356
10.1192/BJP.187.2.131
P407
P577
2005-08-01T00:00:00Z